ARCHIVES

Leter: Payers Must Determine Appropriate Therapies

This article is from The Cancer Letter archive.

Vol. 22 No. 29 | July 19, 1996

Download PDF Visit The Full Archive

Related Articles

FDA Approves Femara As First-Line Treatment For Advanced Breast Cancer.

January 26, 2001

ODAC Nixes Sanofi’s VTE Drug in 14-1 Vote, Setting High Bar For Adjunctive Therapies

June 22, 2012

Conversations With The Cancer Letter: Youle: ACS Stance on Tobacco Sales Is Clear

April 18, 2014

Clinical Trials: Phase I Trial of Karenitecin Begins, BioNumerik Says

March 5, 1999

Accrual Picking Up, Still “Nothing To Write Home About;” Unfunded MDs ‘Subsidizing Entire Program”

June 3, 1988

Cephalon To Plead Guilty, Pay $425M For Off-Label Marketing.

October 3, 2008